NVCT (Nuvectis Pharma) Cash And Cash Equivalents : $18.53 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Cash And Cash Equivalents?

Nuvectis Pharma's quarterly cash and cash equivalents declined from Jun. 2024 ($18.12 Mil) to Sep. 2024 ($17.17 Mil) but then increased from Sep. 2024 ($17.17 Mil) to Dec. 2024 ($18.53 Mil).

Nuvectis Pharma's annual cash and cash equivalents declined from Dec. 2022 ($19.99 Mil) to Dec. 2023 ($19.13 Mil) and declined from Dec. 2023 ($19.13 Mil) to Dec. 2024 ($18.53 Mil).

Nuvectis Pharma Cash And Cash Equivalents Historical Data

The historical data trend for Nuvectis Pharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Cash And Cash Equivalents Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

5.74

19.99

19.13

18.53

Nuvectis Pharma Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial												19.13	19.46	18.12	17.17	18.53

Nuvectis Pharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nuvectis Pharma (NAS:NVCT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nuvectis Pharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Executives

Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024